Related Experiment Video

Updated: Jan 27, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway

Yan-Bo Sui1, Yu Wang2, Li Liu1

  • 1a First Unit of Department of Cardiology , First Affiliated Hospital of Heilongjiang University of Chinese Medicine , Harbin , China.

Pharmaceutical Biology
|March 26, 2019
PubMed

Insights

Astragaloside IV (ASI) treatment improved heart function and survival in a rat model of heart failure (HF). ASI promoted angiogenesis via the JAK-STAT3 pathway, offering new strategies for HF prevention.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Molecular Biology

Background:

  • Heart failure (HF) is a significant global health concern.
  • Astragaloside IV (ASI), a compound from Astragalus, is used in China for cardiovascular diseases.

Purpose of the Study:

  • To assess ASI's protective effects on HF in a rat model.
  • To investigate ASI's role in angiogenesis-related mechanisms in HF.

Main Methods:

  • Induced HF in Sprague-Dawley rats via left coronary artery ligation.
  • Administered vehicle or ASI (0.1–1 mg/kg/day) orally for 6 weeks.
  • Evaluated cardiac function, infarct size, vascular density, and molecular pathways (JAK-STAT3, VEGF).

Main Results:

  • ASI improved rat body weight, survival rates, and cardiac function (ejection fraction, fractional shortening).
  • ASI reduced infarct size by 47% and promoted angiogenesis, increasing vascular density and VEGF/CD31 expression.
  • ASI activated the JAK-STAT3 pathway, enhancing VEGF promoter activity.

Conclusions:

  • ASI alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway.
  • ASI presents a potential therapeutic strategy for preventing heart failure.
Abstract

Keywords:
CD31Left coronary artery ligationRNA interferenceVEGF

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

6.9K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.4K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
363
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.3K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
793
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
854
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
539